RecruitingOBSERVATIONAL

Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor

This project is an 'observational study,' which means researchers will carefully watch how treatments are used in real life. It focuses on people in the UK who have axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA) and have recently started new medicines like bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor (such as adalimumab or etanercept). The study will collect information from your medical notes and also ask you to fill out surveys about your experiences with the treatment. The main goal is to find out how effective these treatments are, both from what doctors observe and how patients themselves feel.

At a glance

Status

Recruiting

Sponsor

Adelphi Real World

Enrolment target

700

Start

07 Jul 2025

Estimated completion

01 Mar 2027

Axial Spondylarthritis (axSpA)Psoriatic Arthritis (PsA)

What is this study about?

This study aims to understand how well certain new treatments work for two types of arthritis: axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). These conditions can cause pain, stiffness, and swelling, affecting joints and sometimes the spine.

Researchers will be looking at people in NHS hospitals across the UK who have recently started specific medicines. These include bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor (like adalimumab or etanercept). By studying how these treatments are used in everyday medical practice, rather than in a highly controlled environment, researchers can get a good idea of their real-world effectiveness.

This is an "observational study," meaning you won't be given a new drug just for the study. Instead, researchers will gather information about treatments you're already receiving as part of your normal care. They will combine details from your medical records with your own insights from surveys. This dual approach helps them understand both the medical outcomes and how patients feel about their treatment experience.

Key takeaways

This study helps understand how well certain arthritis treatments work in the real world.
It's an 'observational' study – you won't get new treatments just for research.
Information comes from your medical records and surveys you fill out.
It focuses on people with axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
Your input is valuable for improving future patient care.
Participation fits around your normal medical appointments.

Who may be eligible?

To be part of this study, you need to have been diagnosed with either axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA). You must also be 18 years old or older.

Crucially, you should have started a new "advanced" treatment for your axSpA or PsA within the month before joining the study. These types of treatments include medicines like bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor (such as adalimumab).

You won't be able to join this study if you are already taking part in another clinical trial when you want to enrol in this one.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Do you have a diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA)?
Are you 18 years old or older?
Have you started a new treatment (like bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor) for your condition in the last month?
Are you NOT currently taking part in another clinical trial?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you won't be asked to do anything extra beyond your usual medical care. There are no special visits, assessments, or medications given specifically for the study. You will continue to see your doctor and receive your treatment as you normally would.

The main way you'll contribute is by filling out some surveys about your experience with your treatment. These surveys will be given to you at different times throughout the study period. Additionally, researchers will look at information from your existing medical records towards the end of the study. The total duration of your participation will depend on how long the study runs, but it will fit in with your ongoing treatment plan.

Potential risks and benefits

Because this is an observational study, you won't be receiving any new or experimental treatments, so there are no extra risks associated with the medications themselves. Your treatment plan will remain entirely decided by you and your doctor. The main 'benefit' of taking part is contributing valuable information that helps researchers and doctors better understand how effective these treatments are for people like you. Your insights can help improve care for others in the future. You always have the right to withdraw from the study at any time without affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Royal National Hospital for Rheumatic Diseases
Verified postcode
Bath, United Kingdom· Recruiting

Common questions

What is an 'observational study'?

It means researchers watch and collect information about treatments you're already taking for your condition, rather than giving you new medicines or specific study treatments.

Will I have to take new medicine for this study?

No, this study only collects information about the treatments you are prescribed by your doctor as part of your normal care.

What kind of information will be collected from me?

The study will collect information from your medical records and ask you to complete surveys about how you feel about your treatment.

Will my doctor know if I take part?

Yes, your medical team will be involved, as they will provide some of the information from your medical records for the study.

Can I leave the study at any time?

Yes, you are free to stop participating in the study at any point without it affecting your medical care.

How to find out more

SpA Extend Team

arwspaextend@adelphigroup.com +441625 577 829 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.